The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction

Endocrinology

Volumn 141, Issue 1, 2000, Pages 60-66

  Tivesten, Åsa ^a   Bollano, Entela ^b   Caidahl, Kenneth ^a   Kujacic, Vuk ^a   Sun, Xiang Ying ^a   Hedner, Thomas ^a   Hjalmarson, Åke ^b   Bengtsson, Bengt Åke ^a   Isgaard, Jörgen ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR 6; HEXARELIN; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG POTENCY; GROWTH HORMONE RELEASE; HEART FUNCTION; HEART INDEX; HEART INFARCTION; HEART PERFORMANCE; HEART STROKE VOLUME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0034454618     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.1.7249     Document Type: Article

References (57)

1. A receptor in pituitary and hypothalamus that functions in growth hormone release
2. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors
3. Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling
4. Hypothalamic growth hormone secretagogue-receptor (GHS-R) expression is regulated by growth hormone in the rat
5. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons
6. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalarnic level
7. Growth hormone-releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6
8. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
9. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors
10. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats
11. Mechanism of action of hexarelin. I. Growth hormone-releasing activity in the rat
12. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep
13. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral-administration in man
14. The GH, prolactin, ACTH and cortisol responses to hexarelin, a synthetic hexapeptide, undergo different age-related variations
15. Effects of repeated doses and continuous infusions of the growth hormonereleasing peptide hexarelin in conscious male rats
16. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency
17. Intranasal administration of the GHRP hexarelin accelerates growth in short children
18. Sixteen weeks of hexarelin therapy in aged dogs: Effects on the somatotrophic axis, muscle morphology, and bone metabolism
19. Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin
20. Growth hormone and the heart
21. Cardiovascular and renal effects of growth hormone
22. Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study
23. Haemodynamic effects of intravenous growth hormone in congestive heart failure
24. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy
25. A placebo controlled study of growth hormone in patients with congestive heart failure
26. Beneficial effects of growth hormone and insulin-like growth factor-I in experimental heart failure in rats treated with chronic ACE inhibition
27. Growth hormone improves cardiac performance in experimental heart failure
28. Growth hormone improves cardiac function in rats with experimental myocardial infarction
29. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction
30. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern and myosin adenosine triphosphate activity of rat left ventricle
31. 2+ handling and enhance cardiac performance
32. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure
33. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: Protection by hexarelin
34. Growth hormone-independent cardioprotective effects of hexarelin in the rat
35. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans
36. Myocardial infarct size and ventricular function in rats
37. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat
38. Review of the various theories for evaluation of left ventricular wall stress
39. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance
40. Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor-I gene
41. A practical approach for quantitating specific mRNAs by solution hybridization
42. Long-term effects on cardiac output and peripheral resistance in patients treated with enalapril after acute myocardial infarction
43. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency
44. Tissue-specific expression of GHS-receptor mRNA in the CNS and peripheral organs of the male rat
45. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues
46. Molecular cloning and gene expression of growth hormone-releasing peptide receptor in rat tissues
47. Binding sites for growth hormone-releasing peptide
48. Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in aortic rings of the hypophysectomized rat
49. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
50. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
51. Proinflammatory cytokines interleukin 1β and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells
52. Effect of long-term administration of hexarelin on the somatotrophic axis in aged rats
53. Growth hormone status during long-term hexarelin therapy
54. Growth hormone-releasing activity of hexarelin in humans
55. Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging
56. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus
57. 2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men